In a nutshell This study investigated the impact of the D-Rd regimen including daratumumab (Darzalex) combined with lenalidomide (Revlimid) and dexamethasone (Decadron) on the quality of life of patients with multiple myeloma (MM) who cannot undergo a transplant. The study showed that patients who received D-Rd reported lower levels of...
Read More
In a nutshell This study aimed to investigate the outcomes for patients with multiple myeloma (MM) who were treated with pomalidomide (Pomalyst), bortezomib (Velcade), and dexamethasone (Decadron) after relapsing following lenalidomide (Revlimid) treatment. This study concluded that this treatment combination was effective in...
Read More
In a nutshell This trial is investigating the effectiveness and side effects of nivolumab (Opdivo) with a dendritic cell vaccine for patients with multiple myeloma (MM). The main outcome of this study would be to see the number of patients that develop an allergic reaction to the treatment. This study is recruiting in Boston, MA, United...
Read More
In a nutshell This study aimed to investigate the safety and effectiveness of a combination of clarithromycin, pomalidomide, and dexamethasone (the ClaPd regime) in patients with relapsed/unresponsive multiple myeloma who had been treated with lenalidomide. This study concluded that this combination is as effective as other currently used...
Read More
In a nutshell This study monitored the development of minimal residual disease (MRD) after transplant for multiple myeloma (MM). The main finding was that different patterns of MRD development are associated with varying success after stem cell transplant for MM. Some background There are many treatments for MM. Patients are often cured fully by...
Read MoreIn a nutshell This study investigated the effects of stem cell transplant and anti-cancer drug treatment for Multiple Myeloma. Stem cell transplant appeared to increase survival in patients with Multiple Myeloma. Some background Multiple myeloma (MM) is a type of cancer in which red blood cells over produce antibodies. Stem cell transplant is a common...
Read MoreIn a nutshell This study investigated the effects of lenalidomide/dexamethasone (Revlimid/Dexasone) combination treatment in relapsed multiple myeloma. The main finding was that the type of relapse may predict how a patient responds to lenalidomide/dexamethasone treatment. Some background Common treatments for multiple myeloma (MM) include...
Read More
In a nutshell This study investigated the effects of adding ixazomib (Ninlaro) to lenalidomide (Revlimid) and dexamethasone (Dexasone) for patients with unresponsive multiple myeloma. The main finding was that patients receiving ixazomib plus lenalidomide and dexamethasone survived longer without worsening of cancer (progression-free...
Read More
In a nutshell This paper reviewed the effect of thearpies that act on the immune system on the risk of infection. The study concluded that patients receiving these drugs are at a high risk of serious infection. Some background Treatment for multiple myeloma now generally includes immunomodulators and stem cell transplantation....
Read More
In a nutshell This study investigated the safety and effectiveness of two different doses of carfilzomib (Kyprolis) for patients with relapsed or refractory multiple myeloma. This study concluded that once weekly carfilzomib is safe and more effective than the twice weekly dose for these patients. Some background Multiple myeloma is a type of cancer...
Read More
In a nutshell This study examined the effects of pomalidomide (Pomalyst) in combination with bortezomib (Velcade) and dexamethasone (Decadron) in patients with relapsed or refractory multiple myeloma. This treatment combination was considered safe and effective for previously treated multiple myeloma. Some background Standard treatment for...
Read More
